Zai-Shang Li1,2,3,4, Xue-Ying Li5, Bin Wang6, Peng Chen7, Xiang Li8, Ornellas Antonio Augusto9, Zi-Ke Qin2,3,4, Zhuo-Wei Liu2,3,4, Yong-Hong Li2,3,4, Hui Han10,11,12, Fang-Jian Zhou13,14,15. 1. Department of Urology, Shenzhen People's Hospital, First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical College of Jinan University, Shenzhen, P. R. China. 2. Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P. R. China. 3. State Key Laboratory of Oncology in Southern China, Guangzhou, P. R. China. 4. Collaborative Innovation Center of Cancer Medicine, Guangzhou, P. R. China. 5. Department of Oncology, The Seventh Affiliated Hospital Sun Yat-Sen University, Shenzhen, Guangdong, P. R. China. 6. Department of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, P. R. China. 7. Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumchi, P. R. China. 8. Department of Urology, West China Hospital, Chengdu, P. R. China. 9. Department of Urology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil. 10. Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P. R. China. hanhui@sysucc.org.cn. 11. State Key Laboratory of Oncology in Southern China, Guangzhou, P. R. China. hanhui@sysucc.org.cn. 12. Collaborative Innovation Center of Cancer Medicine, Guangzhou, P. R. China. hanhui@sysucc.org.cn. 13. Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P. R. China. Zhoufj@sysucc.org.cn. 14. State Key Laboratory of Oncology in Southern China, Guangzhou, P. R. China. Zhoufj@sysucc.org.cn. 15. Collaborative Innovation Center of Cancer Medicine, Guangzhou, P. R. China. Zhoufj@sysucc.org.cn.
Abstract
PURPOSE: Because there is a lack of evidence, it is not generally recommended to use adjuvant radiotherapy plus chemotherapy to treat lymph node disease in penile cancer. The aim of this study was to determine the benefit of using adjuvant radiotherapy after inguinal surgery for penile cancer. METHODS: Multi-institutional data were obtained from a total of nine centers from April 2003 to April 2015 and retrospectively analyzed. pN3 patients with an extracapsular nodal extension who received adjuvant therapy after inguinal surgery were included. Cancer-specific survival (CSS) was estimated using the Kaplan-Meier method. The multivariate analysis was performed using a Cox proportional hazards model. RESULTS: A total of 93 pN3 patients met the inclusion criteria. During the study period, 32 (34.4%) and 61 (65.6%) of these patients received adjuvant radiotherapy plus chemotherapy (AR + AC) or adjuvant chemotherapy alone (AC). The median CSS in all patients was 12.0 months (interquartile range [IQR] 7.5-16.5). The Kaplan-Meier estimated 3-year CSS rate was significantly longer in the AR + AC group (28.5%) than the AC group (16.2%) (p = 0.036). AC + AR was associated with an improvement in CSS by 7.7 months (17.7 [IQR 3.8-31.6] vs. 10.0 [IQR 6.6-13.4] months). In the Cox regression analysis, AR + AC was an independent predictor of CSS [model a: HR 0.486 (95% CI 0.258-0.916), model b: HR 0.527 (95% CI 0.286-0.972)]. CONCLUSION: In conclusions, AR + AC was associated with improved CCS in patients with penile cancer who displayed an extracapsular nodal extension after inguinal surgery. This hypothesis requires further confirmation.
PURPOSE: Because there is a lack of evidence, it is not generally recommended to use adjuvant radiotherapy plus chemotherapy to treat lymph node disease in penile cancer. The aim of this study was to determine the benefit of using adjuvant radiotherapy after inguinal surgery for penile cancer. METHODS: Multi-institutional data were obtained from a total of nine centers from April 2003 to April 2015 and retrospectively analyzed. pN3 patients with an extracapsular nodal extension who received adjuvant therapy after inguinal surgery were included. Cancer-specific survival (CSS) was estimated using the Kaplan-Meier method. The multivariate analysis was performed using a Cox proportional hazards model. RESULTS: A total of 93 pN3 patients met the inclusion criteria. During the study period, 32 (34.4%) and 61 (65.6%) of these patients received adjuvant radiotherapy plus chemotherapy (AR + AC) or adjuvant chemotherapy alone (AC). The median CSS in all patients was 12.0 months (interquartile range [IQR] 7.5-16.5). The Kaplan-Meier estimated 3-year CSS rate was significantly longer in the AR + AC group (28.5%) than the AC group (16.2%) (p = 0.036). AC + AR was associated with an improvement in CSS by 7.7 months (17.7 [IQR 3.8-31.6] vs. 10.0 [IQR 6.6-13.4] months). In the Cox regression analysis, AR + AC was an independent predictor of CSS [model a: HR 0.486 (95% CI 0.258-0.916), model b: HR 0.527 (95% CI 0.286-0.972)]. CONCLUSION: In conclusions, AR + AC was associated with improved CCS in patients with penile cancer who displayed an extracapsular nodal extension after inguinal surgery. This hypothesis requires further confirmation.
Authors: Christian Winter; David Pfister; Jonas Busch; Cigdem Bingöl; Ulrich Ranft; Mark Schrader; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Albers Journal: Eur Urol Date: 2011-11-07 Impact factor: 20.096
Authors: Richard Robinson; Lorenzo Marconi; Ekelechi MacPepple; Oliver W Hakenberg; Nick Watkin; Yuhong Yuan; Thomas Lam; Steven MacLennan; Temitope E Adewuyi; Alberto Coscione; Suks S Minhas; Eva M Compérat; Andrea Necchi Journal: Eur Urol Date: 2018-04-24 Impact factor: 20.096
Authors: Elio Mazzone; Sophie Knipper; Francesco A Mistretta; Zhe Tian; Carlotta Palumbo; Denis Soulieres; Ottavio De Cobelli; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2019-08-28 Impact factor: 4.226
Authors: Oliver W Hakenberg; Eva M Compérat; Suks Minhas; Andrea Necchi; Chris Protzel; Nick Watkin Journal: Eur Urol Date: 2014-11-01 Impact factor: 20.096
Authors: Pranav Sharma; Rosa Djajadiningrat; Kamran Zargar-Shoshtari; Mario Catanzaro; Yao Zhu; Nicola Nicolai; Simon Horenblas; Philippe E Spiess Journal: Urol Oncol Date: 2015-06-10 Impact factor: 3.498
Authors: Antonio Augusto Ornellas; Bernardo Lindenberg Braga Nóbrega; Eduardo Wei Kin Chin; Aristóteles Wisnescky; Paulo Cesar Barbosa da Silva; Aline Barros de Santos Schwindt Journal: J Urol Date: 2008-08-15 Impact factor: 7.450